White hyacinth bean polysaccharide ameliorates diabetes via microbiota-gut-brain axis in type 2 diabetes mellitus rats.

Gut played a potent role in onset and progression of metabolic disorders, presenting an exciting direction for diabetes prevention. Here, the anti-diabetic effects of White hyacinth bean polysaccharides (WHBP) were observed, including the reduction of blood glucose levels and improvement of intestinal impairment in type 2 diabetes mellitus (T2DM) rats. Further data concerning intestinal protection suggested that WHBP restored intestinal barrier, as evidenced by inhibition of intestinal pathological damage, up-regulation of Zonula occluden-1 expression and manipulation of the redox system in T2DM rats. Moreover, WHBP-mediated anti-diabetic effects were in parallel with the adjustment of changes in gut microbiota composition of T2DM rats. Meanwhile, hypersecretion of corticotropin-releasing hormone, adrenocorticotropic hormone, and corticosterone levels, which were critical coordinators of the hypothalamic-pituitary-adrenal (HPA) axis, were suppressed in T2DM rats exposed to WHBP, indicating that WHBP-mediated health benefits were referring to regulate brain feedback in reduction of HPA axis. Concomitantly, further suggested and expanded on gut-brain communication by data of microbial metabolites short-chain fatty acids, mediators of gut-brain interactions, were remarkably raised in cecum contents of T2DM rats subjected to WHBP. Collectively, WHBP performed anti-diabetic effects were associated with control of microbiota-gut-brain axis implicated in intestinal barrier, HPA axis, gut microbiota and their metabolites.

Activity fingerprinting of polysaccharides on oral, gut, pancreas and lung microbiota in diabetic rats.

The modern rise in type 2 diabetes mellitus (T2DM) and its correlation to commensal microbiota have elicited global concern about the patterns of microbial action in the host. With the exception of that linked to gut, microbiota were also colonized in pancreas, oral, and lung, contributing to the physiopathology of T2DM. In this study, we aimed to explore the protective effects of Ganoderma atrum polysaccharide (PSG) and White Hyacinth Bean polysaccharide (WHBP) on the intestine, pancreas, oral, and lung microbiota in T2DM rats. Here we showed that, despite capacities of polysaccharides that exerted similar protective effects on hyperglycemia, dyslipidemia, insulin resistance and dysbacteriosis in T2DM rats, PSG and WHBP were able to be characterized by their own "target" bacteria, which could be proposed for activity-fingerprinting of polysaccharide species. Furthermore, we found a mutual bacteria spectrum in the pancreas and lung, and most bacteria could be tracked to oral or gut samples. Notably, the overlapping areas of the microbiota profile between organs (pancreas, lung) and saliva were more than in the gut, suggesting that a saliva sample was also of interest to serve as a "telltale sign" for judging pancreatic injury. Together, these microbiota interactions provided a new potential to harvest alternative samples for disease surveillance. Meanwhile, polysaccharides had anti-T2DM abilities, which could be distinguished by their own characteristic bacteria.

Chimonanthus nitens Oliv. essential oil mitigates lipopolysaccharide-induced acute lung injury in rats.

This study aimed to evaluate the effect of Chimonanthus nitens Oliv. essential oil (named CEO) on lipopolysaccharide (LPS)-induced acute lung injury (ALI) in rats. In the present study, 21 compounds were characterized in CEO by gas chromatography-mass spectrometry analysis. Furthermore, animal data suggested that CEO could protect rats against ALI, as evidence by increasing white blood cell count, reducing immune organ index and improving lung histopathological changes in rats subjected to LPS. Reduction of the levels of IL-1ß was also shown during CEO-triggering lung protection in rats. Meanwhile, these protective effects of CEO were accompanied by the attenuation of lipid oxidation, and elevation of antioxidant enzymes, suggesting that enhancement of antioxidant defense was linked to its lung protection. Moreover, a combination with CEO and LPS significantly elevated short-chain fatty acids (SCFAs) compared with LPS alone via increasing propionic, i-butyric, butyric and i-valeric acid on LPS-induced ALI in rats. Therefore, our findings indicated that CEO could alleviate LPS-caused ALI in rats by controlling aberrant inflammation, correcting the redox system, and modulating SCFAs in rats.

Protective effect of Ganoderma atrum polysaccharides in acute lung injury rats and its metabolomics.

The present study aimed to evaluate effect of Ganoderma atrum polysaccharide (PSG) on acute lung injury (ALI) rats and its mechanisms. Results showed that PSG exhibited protective effects against ALI by maintaining pulmonary histology, reducing levels of pro-inflammatory cytokines and NO both in serum and lung tissue. Moreover, this study further evaluated the metabolic effects of PSG based on UPLC-Triple-TOF/MS metabolomics analysis in rats. Compared with control group, LysoPC (18:2), LPA (18:1), taurocholic acid, L-histidine, and L-tryptophan were identified as metabolic biomarkers in serum of ALI group. Furthermore, biological pathways analysis demonstrated that histidine metabolism, nitrogen metabolism, tryptophan and part glycerophospholipids metabolism were notably modified by PSG treatment in ALI rats. Additionally, improved gut microbial metabolite short-chain fatty acids were found after intake of PSG in ALI rat. Altogether, PSG could control ALI-induced aberrant inflammation and its mechanisms were linked to inhibit release of pro-inflammatory mediators and reverse metabolic pathway disturbances.

Effects of a Ganoderma atrum polysaccharide against pancreatic damage in streptozotocin-induced diabetic mice.

This study aimed at exploring the role of a Ganoderma atrum polysaccharide (PSG-1) in pancreatic damage in streptozotocin (STZ)-induced type 1 diabetes mellitus (T1DM) mice. The results suggested that blood glucose was significantly increased in the STZ group in comparison with the control group. After 4 weeks of treatment with PSG-1 or metformin (MET), blood glucose levels in the PSG-1 and MET groups were apparently lower than in the STZ group, indicating that PSG-1 triggered hypoglycemic effects in vivo. Moreover, experiments demonstrated that PSG-1 markedly decreased apoptosis of islet cells by inhibiting the mitochondrial apoptotic pathway and activating the PI3K/Akt survival pathway. PSG-1 also exerted anti-inflammatory effects, as evidenced by the dramatically decreased levels of IL-1ß, TNF-α and INF-γ and restraint of the TLR4-dependent NF-κB signal pathway. Meanwhile, PSG-1 maintained homeostasis of redox systems by increasing the activities of anti-oxidant enzymes and decreasing the amount of malondialdehyde in the pancreas. Together, these data provide evidence that PSG-1 can be employed as an alternative dietary supplement to ameliorate T1DM.